Changes between Version 17 and Version 18 of TrialRegistrationDataSetPtBr

Show
Ignore:
Timestamp:
02/23/10 12:44:13 (3 years ago)
Author:
Margareth Prevot <margot.fiocruz@gmail.com> (IP: 157.86.8.4)
Comment:

--

Legend:

Unmodified
Added
Removed
Modified
  • TrialRegistrationDataSetPtBr

    v17 v18  
    2929... 
    3030 
    31 1. Primary Registry and Trial Identifying Number 
    32  
    33 Name of Primary Registry, and the unique ID number assigned by the Primary Registry to this trial. (see: [PrimaryIdNumberField PrimaryIdNumber]) 
     31[1. Primary Registry and Trial Identifying Number 
     32 
     33Name of Primary Registry, and the unique ID number assigned by the Primary Registry to this trial. (see: [PrimaryIdNumberField PrimaryIdNumber]) ] 
    3434 
    3535=== 2. Data de Registro no Rebrac === 
     
    3939... 
    4040 
    41 2. Date of Registration in Primary Registry 
    42  
    43 Date when trial was officially registered in the Primary Registry. (see: [RegistrationDateField RegistrationDate]) 
     41[2. Date of Registration in Primary Registry 
     42 
     43Date when trial was officially registered in the Primary Registry. (see: [RegistrationDateField RegistrationDate]) ] 
    4444 
    4545=== 3. Identificadores secundários do ensaio === 
     
    5656... 
    5757 
    58 3. Secondary Identifying Numbers 
    59  
    60 Other identifying numbers and issuing authorities besides the Primary Registry, if any. Include the sponsor name and sponsor-issued trial number (e.g., protocol number) if available. Also include other trial registries that have issued an identifying number to this trial. There is no limit on the number of Secondary identifying numbers that can be provided. (see: [SecondaryIdNumbersField SecondaryIdNumbers]) 
     58[3. Secondary Identifying Numbers 
     59 
     60Other identifying numbers and issuing authorities besides the Primary Registry, if any. Include the sponsor name and sponsor-issued trial number (e.g., protocol number) if available. Also include other trial registries that have issued an identifying number to this trial. There is no limit on the number of Secondary identifying numbers that can be provided. (see: [SecondaryIdNumbersField SecondaryIdNumbers]) ] 
    6161 
    6262=== 4. Fonte(s) de apoio financeiro ou material === 
     
    6666... 
    6767 
    68 4. Source(s) of Monetary or Material Support 
     68[4. Source(s) of Monetary or Material Support 
    6969 
    7070Major source(s) of monetary or material support for the trial (e.g., funding agency, foundation, company). (see: [SupportSourcesField SupportSources]) 
     
    7676... 
    7777 
    78 5. Primary Sponsor 
     78[5. Primary Sponsor 
    7979 
    8080The individual, organization, group or other legal entity which takes responsibility for initiating, managing and/or financing a study. The Primary Sponsor is responsible for ensuring that the trial is properly registered. The Primary Sponsor may or may not be the main funder. (see: [PrimarySponsorField PrimarySponsor]) 
     
    9393... 
    9494 
    95 6. Secondary Sponsor(s) 
     95[6. Secondary Sponsor(s) 
    9696 
    9797Additional individuals, organizations or other legal persons, if any, that have agreed with the primary sponsor to take on responsibilities of sponsorship. A secondary sponsor may have agreed: 
     
    112112... 
    113113 
    114 7. Contact for Public Queries 
     114[7. Contact for Public Queries 
    115115 
    116116Email address, telephone number, or postal address of the contact who will respond to general queries, including information about current recruitment status. (see [PublicContactField PublicContact]) 
     
    124124... 
    125125 
    126 8. Contact for Scientific Queries 
     126[8. Contact for Scientific Queries 
    127127 
    128128Email address, telephone number, or postal address, and affiliation of the person to contact for scientific queries about the trial (e.g., principal investigator, medical director employed by the sponsor). For a multi-center study, enter the contact information for the lead Principal Investigator or overall scientific director. (see [ScientificContactField ScientificContact]) 
     
    136136... 
    137137 
    138 9. Public Title 
     138[9. Public Title 
    139139 
    140140Title intended for the lay public in easily understood language. (see [PublicTitleField PublicTitle]) 
     
    148148... 
    149149 
    150 10. Scientific Title 
     150[10. Scientific Title 
    151151 
    152152Scientific title of the study as it appears in the protocol submitted for funding and ethical review. Include trial acronym if available. (see [ScientificTitleField ScientificTitle]) 
     
    160160... 
    161161 
    162 11. Countries of Recruitment 
     162[11. Countries of Recruitment 
    163163 
    164164The countries from which participants will be, are intended to be, or have been recruited. (see [RecruitmentCountriesField RecruitmentCountries]) 
     
    174174... 
    175175 
    176 12. Health Condition(s) or Problem(s) Studied  
     176[12. Health Condition(s) or Problem(s) Studied  
    177177 
    178178Primary health condition(s) or problem(s) studied (e.g., depression, breast cancer, medication error). If the study is conducted in healthy human volunteers belonging to the target population of the intervention (e.g. preventive or screening interventions), enter the particular health condition(s) or problem(s) being prevented. If the study is conducted in healthy human volunteers not belonging to the target population (e.g., a preliminary safety study), an appropriate keyword will be defined for users to select. (see [HealthConditionsField HealthConditions]) 
     
    188188... 
    189189 
    190 13. Intervention(s) 
     190[13. Intervention(s) 
    191191 
    192192Enter the specific name of the intervention(s) and the comparator/control(s) being studied. Use the International Non-Proprietary Name if possible (not brand/trade names). For an unregistered drug, the generic name, chemical name, or company serial number is acceptable. If the intervention consists of several separate treatments, list them all in one line separated by commas (e.g., "low-fat diet, exercise"). 
     
    202202... 
    203203 
    204 14. Key Inclusion and Exclusion Criteria 
     204[14. Key Inclusion and Exclusion Criteria 
    205205 
    206206nclusion and exclusion criteria for participant selection, including age and sex. (see [InclusionCriteriaField InclusionCriteria]) 
     
    216216... 
    217217 
    218 15. Study Type 
     218[15. Study Type 
    219219 
    220220A single arm study is one in which all participants are given the same intervention. Trials in which participants are assigned to receive one of two or more interventions are NOT single arm studies. Crossover trials are NOT single arm studies. 
     
    234234... 
    235235 
    236 16. Date of First Enrollment 
     236[16. Date of First Enrollment 
    237237 
    238238Anticipated or actual date of enrollment of the first participant. (see [FirstEnrollmentDateField FirstEnrollmentDate]). 
     
    244244... 
    245245 
    246 17. Target Sample Size 
     246[17. Target Sample Size 
    247247 
    248248Number of participants that this trial plans to enroll. (see [SampleSizeField SampleSize]) 
     
    261261... 
    262262 
    263 18. Recruitment Status 
     263[18. Recruitment Status 
    264264 
    265265Recruitment status of this trial: 
     
    269269  * Complete: participants are no longer being recruited or enrolled 
    270270  * Other 
    271  
    272 (see [RecruitmentStatusField RecruitmentStatus]) 
     271] 
    273272 
    274273=== 19. Desfecho(s) primário(s) === 
     
    284283... 
    285284 
    286 19. Primary Outcome(s) 
     285[19. Primary Outcome(s) 
    287286 
    288287Outcomes are events, variables, or experiences that are measured because it is believed that they may be influenced by the intervention. The Primary Outcome should be the outcome used in sample size calculations, or the main outcome(s) used to determine the effects of the intervention(s). 
     
    290289Enter the names of all primary outcomes in the trial as well as the pre-specified timepoint(s) of primary interest. Be as specific as possible with the metric used (e.g., “% with Beck Depression Score > 10” rather than just “depression”). 
    291290 
    292 Examples: Outcome Name: all-cause mortality, Timepoints: 5 years; or Outcome Name: Mean Beck Depression Score, Timepoint: 18 weeks 
    293  
    294 (see [PrimaryOutcomesField PrimaryOutcomes]) 
     291Examples: Outcome Name: all-cause mortality, Timepoints: 5 years; or Outcome Name: Mean Beck Depression Score, Timepoint: 18 weeks  ] 
    295292 
    296293=== 20. Desfecho Secundários === 
     
    306303... 
    307304 
    308 20. Key Secondary Outcomes 
     305[20. Key Secondary Outcomes 
    309306 
    310307Secondary outcomes are events, variables, or experiences that are of secondary interest or that are measured at timepoints of secondary interest. A secondary outcome may involve the same event, variable, or experience as the primary outcome, but measured at timepoints other than those of primary interest (e.g., Primary outcome: all-cause mortality at 5 years; Secondary outcome: all-cause mortality at 1 year, 3 years), or may involve a different event, variable, or experience altogether (e.g., Primary outcome: all-cause mortality at 5 years; Secondary outcome: hospitalization rate at 5 years). 
     
    312309Enter the name and timepoint(s) for all secondary outcomes of clinical and/or scientific importance. Be as specific as possible with the metric used (e.g., “% with Beck Depression Score > 10” rather than just “depression”). 
    313310 
    314 Examples: Outcome Name: all-cause mortality, Timepoint: 6 months, 1 year; or Outcome Name: Mean glycosylated hemoglobin A1C, Timepoint: 4 and 8 weeks 
    315  
    316 (see [SecondaryOutcomesField SecondaryOutcomes]) 
     311Examples: Outcome Name: all-cause mortality, Timepoint: 6 months, 1 year; or Outcome Name: Mean glycosylated hemoglobin A1C, Timepoint: 4 and 8 weeks ]